Assertio Therapeutics (ASRT) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results
March 6, 2019 4:02 PM EST-- Reports Neurology Franchise Annual Net Sales of $110.3 million, at the High End of Guidance Range --
-- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance --
-- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales --
LAKE FOREST, Ill., March 06, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today reported financial results for the fourth quarter and year ended December 31, 2018, and provided an update on its business performance and strategic initiatives.
... More